Allogene Therapeutics Inc, based in South San Francisco, CA, is a cutting-edge biotechnology company focused on pioneering advancements in cell therapy. Specializing in the development of allogeneic CAR T cell products, their innovative AlloCAR T™ platform aims to revolutionize treatments for blood cancers, solid tumors, and autoimmune diseases.
With a strong emphasis on multiplex gene-engineering and gene-editing capabilities, Allogene Therapeutics' proprietary lymphodepletion platform and state-of-the-art manufacturing processes set them apart in the industry. Their leadership team, comprising key pioneers in CAR T cell products, is dedicated to pushing boundaries and delivering transformative therapies to patients.
By leveraging a scalable and efficient manufacturing approach, Allogene Therapeutics envisions a future where allogeneic cell products can offer broader accessibility, potential for repeat dosing, and streamlined logistics. Their commitment to innovation, reliability, and patient-centric care underscores their mission to redefine the landscape of cell therapy.
Generated from the website content
